SIGA Technologies Inc (SIGA) Options

Charting up today,might be a good holiday swing

SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®

https://investor.siga.com/investors/news/news-details/2024/SIGA-Announces-New-Contract-Awarded-by-U.S.-Department-of-Defense-for-the-Procurement-of-9-Million-of-TPOXX/default.aspx

https://www.cdc.gov/poxvirus/mpox/clinicians/tecovirimat-ea-ind.html

Hell of a bounce back! $6-$9 but will it hold?

Drug fail, oopsie!

Boom town, monkey biz

SIGA under $10

SIGA under $10

SIGA 75k share buy at close almost half a million $, very nice

Break 6.59 and we should touch 8

Bottom in, 5.32

SIGA 1-Yr Chart and Recent News Looking Good

SIGA look at the insider selling

SIGA 6.36 pullin back

nice find...

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®
https://finance.yahoo.com/news/siga-announces-u-government-procurement-204500111.html

https://finviz.com/quote.ashx?t=SIGA&p=d

SIGA

Certainly is a beautiful contract.

Nice picked up some AH

SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®
Exercise of Procurement Options of Approximately $113 Million for Oral TPOXX and Approximately $25 Million for IV TPOXX under Current Contract reflects continuing global action to enhance smallpox preparedness
NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that the U.S. Department of Health and Human Services exercised procurement options for the delivery of approximately $113 million worth of oral TPOXX® treatment courses and approximately $25 million worth of IV TPOXX® treatment courses.

“Building on the orders SIGA received for TPOXX from 13 international customers and the U.S. Department of Defense in 2022, these most recent procurement orders further highlight that many global leaders in public heath recognize the importance of orthopoxvirus preparedness and the need to take action to keep people safe,” said Phil Gomez, CEO of SIGA. “We are pleased that we are able to consistently meet demand for oral TPOXX, which is driving substantial and increasingly diversified global revenue opportunities at SIGA.”

SIGA expects to fully deliver approximately $113 million of oral TPOXX under this order in 2023 and expects to start delivering IV TPOXX under this order in 2024. Prior to delivery of IV TPOXX under this order, SIGA will be focused on fulfilling delivery obligations under a prior IV TPOXX order.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) and Strategic National Stockpile, under Contract No. 75A50118C00019.

This volitile stock is ready for a steady climb.

NIH doing gain of function research to make monkeypox 100 times more deadly. Hey, that’s good for business.

NIH trying to drum up more business for pharma.

STOMP is a NIAID-funded clinical trial led by the ACTG to evaluate the effectiveness of the antiviral tecovirimat, also know as TPOXX, for the treatment of human monkeypox infection.

stomptpoxx.org/main

The team hopes results may be available before Christmas

Oxford University launch new clinical trial to test a treatment for monkeypox

https://www.ox.ac.uk/news/2022-08-24-oxford-university-launch-new-clinical-trial-test-treatment-monkeypox

alert!

Monkeypox infection and resolution after treatment with tecovirimat in two patients with HIV disease

https://journals.sagepub.com/doi/10.1177/20499361221138349

$SIGA

In vitro and in vivo efficacy of Tecovirimat against a recently emerged 2022 Monkeypox virus isolate

approval coming soon$$$$$$$

https://pubmed.ncbi.nlm.nih.gov/36318038/

CHRISTINA HUTSON, CDC [00:20:10]
Because of these findings, from the start of the outbreak, we have been monitoring the F13L gene within sequenced isolates. At this time, CDC has analyzed sequence data for more than 4,000 specimens from across the United States, of which 11 were found to have genetic changes in the F13L gene during those sequence surveillance efforts.
When tested within the lab, using a cell culture based sensitivity assay, those 11 isolates were sensitive to tecovirimat, showing no evidence of resistance.
We’re currently working on a health advisory related, in part, to development of tecovirimat resistance virus during prolonged tecovirimat treatment. We wanted to let everyone know that this would be coming out soon, and there’ll be more information for providers about the potential for tecovirimat resistance.

-And we hope to have that HAN out by the middle of next week-

https://www.getrevue.co/profile/alexander_tin/issues/notes-for-11-14-2022-1459787

Is Monkeypox still about 95+% sexually transmitted ?

Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations

https://www.nature.com/articles/s41564-022-01269-8

ER is good: Approximately $61 Million of International Sales in the Third Quarter –

As of September 30, 2022, we had $109.7 million in cash and cash equivalents compared with $103.1 million at December 31, 2021.

As of September 30, 2022, we had outstanding purchase orders associated with manufacturing obligations in the aggregate amount of approximately $21.8 million.



https://investor.siga.com/news-releases/news-release-details/siga-reports-financial-results-three-and-nine-months-ended-0

Biden Admin Renews Public Health Emergency Over Monkeypox

https://www.zerohedge.com/medical/biden-admin-renews-public-health-emergency-over-monkeypox

WHO declares monkeypox still a global health emergency
WHO kept monkeypox on its highest alert level

https://www.foxnews.com/health/who-declares-monkeypox-still-global-health-emergency

CDC has altered their view and comments about the effectiveness of TPOXX. Their website, updated on Oct 18, now reads:

"While monkeypox symptoms can resolve on their own, treatment for orthopoxviruses is available and can provide relief and decrease disease severity for persons with monkeypox. The treatment is tecovirimat (TPOXX), available as a pill or intravenous (IV) infusion. At this time, TPOXX is available through state and territorial health departments and CDC."

https://www.cdc.gov/poxvirus/monkeypox/health-departments/intervention-services.html

IN CENTRAL AFRICA, A DEADLY MONKEYPOX VARIANT IS SURGING

https://www.nationalgeographic.co.uk/science-and-technology/2022/10/in-central-africa-a-deadly-monkeypox-variant-is-surging/amp



New York and Nevada report first monkeypox deaths

https://news.yahoo.com/u-monkeypox-deaths-rise-4-184822233.html

Mass General Brigham studying whether antiviral tecovirimat helps treat monkeypox

https://www.bostonherald.com/2022/10/19/mass-general-brigham-studying-whether-antiviral-tecovirimat-helps-treat-monkeypox/

a 2week old infant....."A 2-week course of enteral tecovirimat (at a dose of 50 mg twice a day) was commenced in combination with intravenous cidofovir. After 4 weeks in intensive care, including 14 days of invasive ventilation, the infant recovered and was discharged home."

https://www.nejm.org/doi/full/10.1056/NEJMc2210828

Almost back to where it started......

https://www.nih.gov/news-events/news-releases/monkeypox-treatment-trial-begins-democratic-republic-congo

SIGA winner

SIGA Provides Update on Progress in Clinical Trials
SIGA disclosed that the Company had received, as of mid September, approximately $76 million of international orders for oral TPOXX from twelve international customers.

https://investor.siga.com/news-releases/news-release-details/siga-provides-update-progress-clinical-trials-assess-use-tpoxx-r

Monkeypox: A dangerous variant circulating in the DRC could go global


https://www.newscientist.com/article/2341569-monkeypox-a-dangerous-variant-circulating-in-the-drc-could-go-global/


$SIGA

CEO: https://www.edisongroup.com/edison-tv/siga-technologies-executive-interview-3/

$SIGA

Q3 ended last week. At least $80m in sales compared to $9m reported Q2. Nov 4'ish should have the Q3 pr$$$$$$$$

The monkeypox virus is mutating. Are scientists worried


If health officials detect an uptick in the number of virus samples carrying these mutations, that could be a possible signal that they are helping the virus to spread.

The good news is that, although the monkeypox virus continues to evolve, no mutations have affected the part of its genome that encodes a protein targeted by tecovirimat, an antiviral drug being tested for use against monkeypox in humans.

https://www.nature.com/articles/d41586-022-03171-z

Awesome DD you are sharing here, many thanks.

I am close to buying more shares... Looking for the bottom to add..

To score grant R&D money for testing improved versions, just in case?

"and say a mutation may be one amino acid away from rendering this drug totally useless"

NEWS OUT: SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®

https://investor.siga.com/news-releases/news-release-details/siga-technologies-announces-new-contract-awarded-us-department

SIGA expects to complete delivery of these most recent orders in 2022. To date this year, including the recent orders, SIGA has received approximately $76 million of international orders for oral TPOXX (tecovirimat) from twelve international customers. It is currently expected that at least $65 million of these orders will be delivered in 2022.

news: SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
September 26, 2022 at 10:07 AM EDT

https://investor.siga.com/news-releases/news-release-details/siga-announces-approximately-16-million-international

Today, the Commission has secured over 10,000 treatment courses of tecovirimat to treat Monkeypox.

https://ec.europa.eu/commission/presscorner/detail/en/ip_22_5482

approval in brazil: https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2022/anvisa-aprova-liberacao-do-medicamento-para-monkeypox-para-uso-pelo-ministerio-da-saude

SIGA Technologies has now secured the rights to sell TPOXX to commercial customers and is working to make this life-saving medication more widely available


https://stock.vi.app/market-price/siga-technologies-to-sell-tpoxx-to-commercial-customers/


winners$$$$$$$$$$$

Vanderbilt researchers are developing an artificial intelligence algorithm that can precisely track and count monkeypox lesions. They are also spearheading the effort to develop lesion classification guidelines, which will be used when evaluating the potential use of tecovirimat, an antiviral that is FDA-approved against smallpox, as a therapy for monkeypox.

https://news.vanderbilt.edu/2022/09/15/vanderbilt-nih-and-the-institut-national-de-recherche-biomedicale-team-up-to-tackle-monkeypox%e2%80%af/